Dr Standiford Helm, MD | |
101 The City Dr S, Orange, CA 92868-3201 | |
(714) 880-7812 | |
Not Available |
Full Name | Dr Standiford Helm |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 101 The City Dr S, Orange, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437156627 | NPI | - | NPPES |
050015007 | Other | CA | MEDICARE RAILROAD IND. # |
1982635322 | Other | CA | GROUP NPI # |
00382460 | Other | CA | BLUE SHIELD |
W15225 | Other | CA | MEDICARE PTAN # |
DE3952 | Other | CA | MEDICARE RAILROAD GRP # |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | G38246 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Standiford Helm, MD 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Dr Standiford Helm, MD 101 The City Dr S, Orange, CA 92868-3201 Ph: (714) 880-7812 |
News Archive
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
Now, breakthrough research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself. The new research could pave the way for effective treatments for a wide range of infectious diseases, including the coronavirus disease (COVID-19).
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
The American Clinical Laboratory Association's Results for Life Campaign (RFL) today recognized the National Changing Diabetes Program (NCDP) for funding a newly published study on quality measurement in diabetes care.
With the renewed and growing interest in nuclear energy, radioecology experts at the U.S. Department of Energy's Savannah River National Laboratory recognized an immediate need to build the pool of radioecology expertise both here and abroad.
› Verified 3 days ago
Calvin J. Okey, DO Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 The City Dr S, Uci Medical Center, Orange, CA 92868 Phone: 714-456-6369 | |
Daniel Quoc Le, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 280 S Main St Ste 200, Orange, CA 92868 Phone: 714-634-4567 |